Article
Clinical trial: extended treatment duration of peginterferon-alpha2b plus ribavirin for 72 and 96 weeks in hepatitis C genotype 1-infected late responders.
Alimentary pharmacology & therapeutics - 15 Aug 2009
Nagaki M, Shimizu M, Sugihara J I, Tomita E, Sano C, Naiki T, Kimura K, Amano K, Sakai T, Ninomiya M, Kojima T, Katsumura N, Fujimoto M, Moriwaki H
Abstract excerpt
BACKGROUND: The benefits of prolonging peginterferon and ribavirin after 48 weeks of treatment to maximize sustained virological responses (SVR) in hepatitis C virus (HCV) genotype 1-infected patients remain to be understood. AIM: To investigate whether extended treatment longer than 72 weeks may be superior to 72-week treatment. METHODS: A total of 120 treatment-naïve or retreated patients with HCV genotype 1...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.